(4R,6R)-6-butyl-4-hydroxy-δ-lactone | 1001855-66-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酯类
• 英文名称: (4R,6R)-6-butyl-4-hydroxy-δ-lactone
• 英文别名: (4R,6R)-6-butyl-4-hydroxyoxan-2-one
• CAS: 1001855-66-8
• 化学式: C₉H₁₆O₃
• 分子量: 172.224
• InChiKey: CSWOPZYVOKHPFF-HTQZYQBOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  (2R,4R)-4-hydroxy-1,2-epoxyoctane 、 一氧化碳 在 hydridotetracarbonylcobalt 作用下， 以 乙二醇二甲醚 为溶剂， 60.0 ℃ 、5.52 MPa 条件下， 反应 24.0h， 生成 (4R,6R)-6-butyl-4-hydroxy-δ-lactone
  参考文献：
  名称：

  Substituted 3-hydroxy-delta-lactones from epoxides

  摘要：

  揭示了用于将环氧化合物羰基化为取代的3-羟基-δ-内酯和β-内酯的催化剂和方法。

  公开号：

  US20100145046A1

文献信息

• COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE
  申请人：Griffin John

  公开号：US20080021054A1

  公开（公告）日：2008-01-24

  The present invention provides compositions of matter, kits and methods for their use in the treatment of MAP kinase-related conditions and/or HMG-CoA reductase-related conditions. In particular, the invention provides compositions for treating inflammatory and/or cardiovascular conditions in an animal subject by inhibiting p38α MAP kinase and/or HMG-CoA reductase, as well as providing formulations and modes of administering such compositions. The invention further provides methods for the rational design of inhibitors of MAP kinase, HMG-COA reductase, or both for use in the practice of the present invention.

  本发明提供了物质组合物、试剂盒以及它们在治疗与MAP激酶相关的疾病和/或HMG-COA还原酶相关的疾病中的使用的方法。特别地，本发明提供了一种治疗动物主体的炎症和/或心血管疾病的组合物，通过抑制p38α MAP激酶和/或HMG-COA还原酶，并提供了这种组合物的制剂和给药方式。本发明还提供了合理设计MAP激酶、HMG-COA还原酶或两者的抑制剂的方法，以用于本发明的实践。
• SUBSTITUTED 3-HYDROXY-DELTA-LACTONES FROM EPOXIDES
  申请人：Cornell University

  公开号：US20140107339A1

  公开（公告）日：2014-04-17

  Catalysts and methods for the carbonylation of epoxides to substituted 3-hydroxy-δ-lactones and β-lactones are disclosed.

  本发明揭示了催化剂和方法，用于将环氧化合物羰基化为取代的3-羟基-δ-内酯和β-内酯。
• Carbonylation of Epoxides to Substituted 3-Hydroxy-δ-Lactones
  作者：John W. Kramer、Daniel Y. Joh、Geoffrey W. Coates

  DOI：10.1021/ol702475e

  日期：2007.12.1

  Substituted 3-hydroxy-delta-lactones (3HLs) are valuable intermediates in the synthesis of pharmaceuticals and other biologically active-natural products. Herein we report the first example of the catalytic carbonylation of substituted homoglycidols to 3HLs using HCo(CO)(4). Upon optimization of the catalyst and reaction conditions, a functionally diverse set of 3HLs was prepared. Mechanistic insight was gained by observation of the carbonylation reaction using in situ IR spectroscopy, and we propose a mechanism that is consistent with previously studied epoxide carbonylation systems.
• US8530677B2
  申请人：——

  公开号：US8530677B2

  公开（公告）日：2013-09-10
• US9676743B2
  申请人：——

  公开号：US9676743B2

  公开（公告）日：2017-06-13